SUMMARY
This article defines some of the terms used in chiral chemistry and some of the basic mechanistic
issues that arise in stereochemistry in pharmacology. Attention is also drawn to the impact of
stereochemistry on drug regulation and its significance for new drug development. The
stereoselectivity of drugs is underpinned by the fact that the human body is essentially a chiral
structure. The rationale for development of chiral drugs is the suggestion that single stereoisomer
drugs would provide superior therapy by allowing reductions in dosage, reduced variability in
metabolism and response, simpler dose-response relationships and improved tolerability.
KEY WORDS
chiral drug; stereoisomer; enantiomer; stereochemistry; stereopharmacology
REFERENCES
Almansa C, Gomez LA, Cavalcanti FL,
de Arriba AF, Rodriguez R, Carceller E,
Garcia-Rafanell J, Forn J: Diphenylpropionic
acids as new AT1 selective angiotensin II
antagonists. J Med Chem 39:2197-2206, 1996.
Ariens EJ: Stereochemistry, a basis for
sophisticated nonsense in pharmacokinetics and
clinical pharmacology. Eur J Clin Pharmacol
26:663-668, 1984.
Burke WJ, Kratochvil ChJ: Stereoisomers in
psychiatry: the case of escitalopram. J Clin
Psychiatry 4:20-24, 2002.
Cahn RS, Ingold CK, Prelog V: Specification of
molecular chirality. Angew Chem 78:413-447, 1966.
Cheng H, Rogers JD, Demetriades JL,
Holland SD, Seibold JR, Depuy E:
Pharmacokinetics and bioinversion of ibuprofen
enantiomers in humans. Pharm Res 11:824-830, 1994.
Chon EM, Middleton RK: Labetalol hepato
toxicity. Ann Pharmacother 26:344-345, 1992.
Herdevall BM, Klinge B, Persson L, Huledal G,
Abdel-Rehim M: Plasma levels of lidocaine,
o-toluidine, and prilocaine after application of
8.5 g Oraqix in patients with generalized
periodontitis: effect on blood methemoglobin
and tolerability. Acta Odontol Scand 61:230-234, 2003.
Hutt AJ, Tan SC: Drug chirality and its
clinical significance. Drugs 52, Suppl. 2:1-12, 1996.
Lalonde RL, O'Rear TL, Wainer IW, Drda KD,
Herring VL, Bottorff MB: Labetalol
pharmacokinetics and pharmacodynamics:
evidence of stereoselective disposition. Clin
Pharmacol Ther 48:509-519, 1990.
Palareti G, Legnani C: Warfarin withdrawal.
pharmacokinetic-pharmacodynamic considerations.
Clin Pharmacokinet 30:300-313, 1996.
Patocka J, Plucar B: Pharmacology and toxicology
of absinthe. J Appl Biomed 1:199-205, 2003.
Pohl LR, Bales R, Trager WF: Warfarin - stereochemical aspects of its metabolism in vivo
in the rat. Res. Commun Chem Pathol
Pharmacol 15:233-256, 1976.
Rybak LP, Whitworth C: Ototoxicity of
indacrinone is stereospecific. Hear Res 31:169-174, 1987.
Sanchez C, Bergqvist PB, Brennum LT,
Gupta S, Hogg S, Larsen A, Wiborg O:
Escitalopram, the S-(+)-enantiomer of
citalopram, is a selective serotonin reuptake
inhibitor with potent effects in animal models
predictive of antidepressant and anxiolytic
activities. Psychopharmacology (Berl). 167:353-362, 2003.
Schwarz UI: Clinical relevance of genetic
polymorphisms in the human CYP2C9 gene.
Eur J Clin Invest 33, Suppl. 2:23-30, 2003.
|
CITED
Hashim NH, Shafie S, Khan SJ. Enantiomeric fraction as an indicator of pharmaceutical biotransformation during wastewater treatment and in the
environment - a review. Environ Technol. 31: 1349-1370, 2010.
Nunez MC, Garcia-Rubino ME, Conejo-Garcia A, Cruz-Lopez O, Kimatrai M, Gallo MA, Espinosa A, Campos JM. Homochiral Drugs: A Demanding Tendency of
the Pharmaceutical Industry. Curr Med Chem. 16: 2064-2074, 2009.
Ivanov IT, Tsokeva Z. Effect of Chirality on PVP/Drug Interaction Within Binary Physical Mixtures of Ibuprofen, Ketoprofen, and Naproxen: A DSC
Study. Chirality. 21: 719-727, 2009.
Valliappan K, Kannan K, Sivakumar T, Manavalan R. Enantiospecific pharmacokinetic studies on ketoprofen in tablet formulation using indirect chiral
HPLC analysis. J Appl Biomed. 4: 153-161, 2006.
|
